Since RIME is induced by TNF‐α and upregulated in cancer cells, targeting RIME might reduce the adverse effect of epigenetic modifier inhibitors on normal cells and has tremendous potential to improve antitumour immune responses. This evidence concerns the gene TNF and cancer.